Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.032x

Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥399.43 Million ≈ $58.45 Million USD) by net assets (CN¥12.43 Billion ≈ $1.82 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Shenzhen Hepalink Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.

Shenzhen Hepalink Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Shenzhen Hepalink Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.

Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Spectrum Brands Holdings Inc NYSE:SPB	0.035x
Gorman-Rupp Company NYSE:GRC	0.036x
Novocure Ltd NASDAQ:NVCR	-0.041x
Walker & Dunlop Inc NYSE:WD	-0.533x
Hunan Nanling Industrial Explosive Materials Co Ltd SHE:002096	0.041x
EZCORP Inc NASDAQ:EZPW	0.042x
UIE PLC CO:UIE	0.044x
Burckhardt Compression SW:BCHN	0.100x

Annual Cash Flow Conversion Efficiency for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual cash flow conversion efficiency of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Shenzhen Hepalink Pharmaceutical Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥12.08 Billion ≈ $1.77 Billion	CN¥1.71 Billion ≈ $250.66 Million	0.142x	-21.14%
2024-12-31	CN¥12.20 Billion ≈ $1.79 Billion	CN¥2.19 Billion ≈ $321.07 Million	0.180x	+441.34%
2023-12-31	CN¥11.99 Billion ≈ $1.75 Billion	CN¥398.22 Million ≈ $58.27 Million	0.033x	+154.47%
2022-12-31	CN¥12.41 Billion ≈ $1.82 Billion	CN¥-756.61 Million ≈ $-110.72 Million	-0.061x	-10499.68%
2021-12-31	CN¥11.52 Billion ≈ $1.69 Billion	CN¥-6.63 Million ≈ $-970.08K	-0.001x	-118.04%
2020-12-31	CN¥11.69 Billion ≈ $1.71 Billion	CN¥37.28 Million ≈ $5.46 Million	0.003x	+110.47%
2019-12-31	CN¥7.47 Billion ≈ $1.09 Billion	CN¥-227.60 Million ≈ $-33.31 Million	-0.030x	-128.48%
2018-12-31	CN¥6.24 Billion ≈ $913.80 Million	CN¥667.87 Million ≈ $97.73 Million	0.107x	+301.93%
2017-12-31	CN¥7.69 Billion ≈ $1.12 Billion	CN¥-407.12 Million ≈ $-59.57 Million	-0.053x	-223.79%
2016-12-31	CN¥8.09 Billion ≈ $1.18 Billion	CN¥346.07 Million ≈ $50.64 Million	0.043x	-57.90%
2015-12-31	CN¥8.79 Billion ≈ $1.29 Billion	CN¥893.71 Million ≈ $130.78 Million	0.102x	-7.00%
2014-12-31	CN¥8.35 Billion ≈ $1.22 Billion	CN¥912.80 Million ≈ $133.57 Million	0.109x	+109.44%
2013-12-31	CN¥8.07 Billion ≈ $1.18 Billion	CN¥420.97 Million ≈ $61.60 Million	0.052x	-11.41%
2012-12-31	CN¥8.05 Billion ≈ $1.18 Billion	CN¥473.89 Million ≈ $69.35 Million	0.059x	-66.83%
2011-12-31	CN¥7.91 Billion ≈ $1.16 Billion	CN¥1.41 Billion ≈ $205.63 Million	0.178x	+301.45%
2010-12-31	CN¥8.02 Billion ≈ $1.17 Billion	CN¥354.86 Million ≈ $51.93 Million	0.044x	-86.70%
2009-12-31	CN¥1.07 Billion ≈ $156.62 Million	CN¥355.81 Million ≈ $52.07 Million	0.332x	+155.03%
2008-12-31	CN¥307.83 Million ≈ $45.05 Million	CN¥40.13 Million ≈ $5.87 Million	0.130x	+37.85%
2007-12-31	CN¥146.44 Million ≈ $21.43 Million	CN¥13.85 Million ≈ $2.03 Million	0.095x	-87.95%
2006-12-31	CN¥91.33 Million ≈ $13.36 Million	CN¥71.66 Million ≈ $10.49 Million	0.785x	--

About Shenzhen Hepalink Pharmaceutical Co Ltd

SHE:002399 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.77 Billion

CN¥12.11 Billion CNY

Market Cap Rank

#6503 Global

#1296 in China

Share Price

CN¥9.71

Change (1 day)

+0.21%

52-Week Range

CN¥8.65 - CN¥13.47

All Time High

CN¥28.69